Indications and uses
Malathion Lotion is indicated for patients infected with Pediculus humanus capitis (head lice and their ova) of the scalp hair.
Malathion Lotion is indicated for patients infected with Pediculus humanus capitis (head lice and their ova) of the scalp hair.
Apply Malathion Lotion on DRY hair in amount just sufficient to thoroughly wet the hair and scalp. Pay particular attention to the back of the head and neck while applying Malathion Lotion. Wash hands after applying to scalp. Allow hair to dry naturally—use no electric heat source, and allow hair to remain uncovered. After 8 to 12 hours, the hair should be shampooed. Rinse and use a fine-toothed(nit) comb to remov...
Rx Only
For topical use only. Not for oral or ophthalmic use.
Malathion Lotion contains 0.005 g of malathion per mL in a vehicle of isopropyl alcohol (78%), terpineol, dipentene, and pine needle oil. The chemical name of malathion is (±) - [(dimethoxyphosphinothioyl) - thio] butanedioic acid diethyl ester. Malathion has a molecular weight of 330.36, represented by C10H19O6PS2, and has the following chemical structure:
Malathion is an organophosphate agent which acts as a pediculicide by inhibiting cholinesterase activity in vivo. Inadvertent transdermal absorption of malathion has occurred from its agricultural use. In such cases, acute toxicity was manifested by excessive cholinergic activity, i.e., increased sweating, salivary and gastric secretion, gastrointestinal and uterine motility, and bradycardia (see OVERDOSAGE). Because the potential for transdermal absorption of malathion from Malathion Lotion is not known at this time, strict adherence to the dosing instructions regarding its use in children, method of application, duration of exposure, and frequency of application is required.
Malathion Lotion is indicated for patients infected with Pediculus humanus capitis (head lice and their ova) of the scalp hair.
Malathion Lotion is contraindicated for neonates and infants because their scalps are more permeable and may have increased absorption of malathion. Malathion Lotion should also not be used on individuals known to be sensitive to malathion or any of the ingredients in the vehicle.
Keep out of reach of children. Close eyes tightly during product application. If accidentally placed in the eye, flush immediately with water. Use only on scalp hair.
There are no special laboratory tests needed in order to use this medication.
Although carcinogenesis, mutagenesis, and impairment of fertility have not been studied with Malathion Lotion, malathion has been shown to be genotoxic in a number of in vitro and in vivo mutation and clastogenicity assays. However, there was no evidence of a carcinogenic effect following long-termoral administration of malathion in F344 rats after 2 years feeding with up to 0.4% (∼ 200 - 400 mg/kg/day) nor was it tumorigenic in Osborne - Mendel rats or B6C3F1 mice after similar feeding for 80 weeks with 0.8% (∼ 400 - 600 mg/kg/day) or 1.6% (∼ 1,000 - 2,000 mg/kg/day), respectively. Based on body surface area, doses tested are approximately 4 to 40 fold greater than those anticipated in humans (assuming 100% bioavailability).
Reproduction studies performed with malathion in rats at doses over 180 fold greater than those anticipated in a 60 kg adult (based on body surface area and assuming 100% bioavailability) revealed no evidence of impaired fertility.
Pregnancy Category B. There was no evidence of teratogenicity in studies in rats and rabbits at doses up to 900 mg/kg/day and 100 mg/kg/day malathion, respectively. A study in rats failed to show any gross fetal abnormalities attributable to feeding malathion up to 2,500 ppm (∼ 200 mg/kg/day) in the diet during a three-generation evaluation period.
These doses were approximately 40 to 180 times higher than the dose anticipated in a 60 kg adult (based on body surface area and assuming 100% bioavailability). Because animal reproduction studies are not always predictive of human responses, this drug should be used (or handled) during pregnancy only if clearly needed.
Malathion in an acetone vehicle has been reported to be absorbed through human skin to the extent of 8% of the applied dose. However, percutaneous absorption from the Malathion Lotion, 0.5% formulation has not been studied, and it is not known whether malathion is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Malathion Lotion is administered to (or handled by) a nursing mother.
The safety and effectiveness of Malathion Lotion in children less than 6 years of age has not been established via well-controlled trials.
Malathion has been shown to be irritating to the skin and scalp. Accidental contact with the eyes can result in mild conjunctivitis. It is not known if Malathion Lotion has the potential to cause contact allergic sensitization.
Consideration should be given, as part of the treatment program, to the high concentration of isopropyl alcohol in the vehicle.
Malathion, although a weaker cholinesterase inhibitor than some other organophosphates, may be expected to exhibit the same symptoms of cholinesterase depletion after accidental ingestion orally. If accidentally swallowed, vomiting should be induced promptly or the stomach lavaged with 5% sodium bicarbonate solution.
Severe respiratory distress is the major and most serious symptom of organophosphate poisoning requiring artificial respiration, and atropine may be needed to counteract the symptoms of cholinesterase depletion.
Repeat analyses of serum and RBC cholinesterase may assist in establishing the diagnosis and formulating a long-range prognosis.
Further treatment is generally not necessary. Other family members should be evaluated by a physician to determine if infested, and if so, receive treatment.
Two controlled clinical trials evaluated the pediculicidal activity of Malathion Lotion. Patients applied the lotion to the hair and scalp in quantities, up to a maximum of 2 fl. oz., sufficient to thoroughly wet the hair and scalp. The lotion was allowed to air dry and was shampooed with Prell shampoo 8 to 12 hours after application. Patients in both the Malathion Lotion group and in the vehicle group were examined immediately after shampooing, 24 hours after, and 7 days after for the presence of live lice. Results are shown in the following table:
| Treatment | Immediately After | 24 Hrs. After | 7 Days After |
|---|---|---|---|
| Malathion Lotion | 129/129 | 122/129 | 114/126 |
| Malathion Vehicle | 105/105 | 63/105 | 31/105 |
The presence or absence of ova at day 7 was not evaluated in these studies. The presence or absence of live lice or ova at 14 days following treatment was not evaluated in these studies.
The residual amount of malathion on hair and scalp is unknown.
Malathion Lotion, USP 0.5%, is supplied in bottles of 2 fl. oz. (59 mL) NDC 42043-150-23.
Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP].
Flammable. Keep away from heat and open flame.
Distributed by: Karalex Pharma, LLC, Woodcliff Lake, NJ 07677 USA
P088828
129059


| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 42043-150-23 | ML - Milliliter | 42043-150 | 18cd874a-9f8e-42a2-9714-4d5046b31da3 | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| MALATHION | ACTIVE INGREDIENT | U5N7SU872W | 3 | |
| MALATHION | ACTIVE MOIETY | U5N7SU872W | 3 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 42043-150 | 42043-150-23 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| MALATHION | U5N7SU872W | ACTIB |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A078743-001 | MALATHION | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | c2088c7a36db… | ||
| 2026-09-14 22:38:34 | 2026-08 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | 782e0a99824c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | 87673890dc5c… | ||
| 2021-03-12 10:30 UTC | 2021-03 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | 5aa47cf7b7d7… | ||
| 2020-12-22 03:56 UTC | 2020-12 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | ea99ee380514… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A078743-001 | MALATHION | 0.5% | LOTION / TOPICAL | 2009-03-06 | 3a93d1ddd44b… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| d451414f-7f29-42d9-918f-76c0c6b7f63c | 6937e1ff-2dc0-47b7-902a-1c9d237e3233 | 2019-12-30 | Warnings, Adverse reactions | 6937e1ff-2dc0-47b7-902a-1c9d237e3233 |
Adverse event summaries are temporarily unavailable. Other product information remains available.